Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amoxicillin + saccharomyces boulardii CNCM I-745
- Development stage
- Unknown
- Lead developer
- Biocodex
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Amoxicillin + saccharomyces boulardii CNCM I-745 is a combination therapy consisting of the antibiotic amoxicillin and the probiotic yeast Saccharomyces boulardii CNCM I-745. Amoxicillin is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis, leading to bacterial cell death. Saccharomyces boulardii CNCM I-745 is a non-pathogenic, single-strain yeast probiotic that helps prevent and treat diarrhea, particularly antibiotic-associated diarrhea, by restoring intestinal microbiota balance and exerting anti-inflammatory effects in the gut. The probiotic can also reduce dysbiosis caused by antibiotics and may help protect against opportunistic pathogens such as Candida albicans[2][3][4][5][6].
02
Targets
PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on amoxicillin + saccharomyces boulardii CNCM I-745.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amoxicillin + saccharomyces boulardii CNCM I-745.